Acute erythroid leukemia, or AEL, is a rare and aggressive type of acute myeloid leukemia (AML) that affects the blood and bone marrow. AEL is characterized by the uncontrolled growth of immature red blood cells, called erythroblasts, which eventually crowd out healthy blood cells.
One of the most significant challenges in treating AEL is achieving remission, which is a period when no signs of cancer can be detected in the body. Unfortunately, not all patients with AEL achieve remission, which can lead to a poorer prognosis and a higher risk of relapse.
Overall, the prognosis for patients with AEL who don't achieve remission is poor. However, there are alternative treatment options available, such as clinical trials and palliative care, that can help to improve a patient's quality of life.
Acute erythroid leukemia (AEL) is a rare form of blood cancer that affects the bone marrow's ability to produce red blood cells. It is a subtype of acute myeloid leukemia (AML) and is characterized by the presence of a high number of immature red blood cells in the blood and bone marrow. In some cases, patients with AEL do not respond ...
To see full information about treatment please Sign up or Log in